Bank Of America Corp Aerie Pharmaceuticals Inc Transaction History

Bank Of America Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$6.37 - $15.23 $9.67 Million - $23.1 Million	-1,518,615 Reduced 58.41%	1,081,133 $16.4 Million
Q2 2022 Aug 12, 2022	SELL	$4.95 - $9.16 $845,974 - $1.57 Million	-170,904 Reduced 6.17%	2,599,748 $19.5 Million
Q1 2022 May 16, 2022	BUY	$5.64 - $9.8 $2.35 Million - $4.08 Million	416,759 Added 17.71%	2,770,652 $25.2 Million
Q4 2021 Feb 08, 2022	SELL	$7.02 - $13.33 $1.92 Million - $3.66 Million	-274,204 Reduced 10.43%	2,353,893 $16.5 Million
Q3 2021 Nov 15, 2021	BUY	$11.32 - $16.63 $24,790 - $36,419	2,190 Added 0.08%	2,628,097 $30 Million
Q2 2021 Sep 13, 2021	BUY	$15.16 - $18.97 $39.8 Million - $49.8 Million	2,625,907 New	2,625,907 $42 Million

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.